Synthorx, Inc., a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of
IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California. The company trades on NASDAQ exchange. The company headquarter is located in LA Jolla, CA. The company was established in the 2014.
| Ticker | THOR |
| Long Name | Synthorx, Inc. |
| Short Name | Synthorx |